EUVIMEDEUVIMED entdecken
Open Access

The role of regional and practice trial sites in nonrepresentative randomized cancer trial enrollment

Sachin J Shah iD, Christopher R Manz iD, Brendan Balthis, Hari S Raman iD, Jason Abaluck iD, Nancy L Keating iD, Leila Agha iD

JNCI: Journal of the National Cancer Institute · 01.12.2025 · 117 (12) · 2672-2676

DOI: 10.1093/jnci/djaf071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 19.03.2025. Verfasst von Sachin J Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Aging and Serious Illness and Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, United States. Hauptthemen laut MEDLINE: Neoplasms, Patient Selection, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Representative trials are critical to advancing cancer treatment, yet little is known about how geographic siting contributes to nonrepresentative enrollment. Using patient-level data, we determined how the choice of trial-enrolling regions and practices impacts representativeness. We created a Surveillance, Epidemiology, and End Results–Medicare cohort of people aged 65 years and older with lung, breast, pancreatic, or renal cancer (2014-2019). We identified randomized cancer drug trial participants and determined their prevalence by advanced age (those aged 75 years and older), sex, race, ethnicity, and rural residence in the full cohort, trial-enrolling regions, trial-enrolling practices, and trials. The choice of region and practice contributed to more than 50% of the underenrollment of Black, Hispanic, and rural patients. Cancer trials enrolled 45% fewer Black patients than expected with proportional representation. Trial recruitment in regions and practices with proportionately fewer Black patients accounted for 27% and 35% of this disparity, respectively. These findings suggest that diversifying cancer trials requires changing the regions and practices referring and enrolling patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPatient SelectionRandomized Controlled Trials as TopicAgedAged, 80 and overFemaleHumansMaleBlack or African AmericanHealthcare DisparitiesMedicareRural PopulationSEER ProgramUnited StatesWhiteRacial Groups

Autor:innen und Institutionen

  • Center for Aging and Serious Illness and Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, United States.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Department of Economics, Yale School of Management, New Haven, CT, United States.
  • Department of Health Care Policy, Harvard Medical School, Boston, MA, United States.
  • Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, United States.

ORCID-Profile: Sachin J Shah, Christopher R Manz, Hari S Raman, Jason Abaluck, Nancy L Keating, Leila Agha

Förderung

  • NIA NIH HHS
  • NIA

Zitieren

APA

Shah, S. J., Manz, C. R., Balthis, B., Raman, H. S., Abaluck, J., Keating, N. L., & Agha, L. (2025). The role of regional and practice trial sites in nonrepresentative randomized cancer trial enrollment. JNCI: Journal of the National Cancer Institute, 117(12), 2672-2676. https://doi.org/10.1093/jnci/djaf071

Vancouver

Shah SJ, Manz CR, Balthis B, Raman HS, Abaluck J, Keating NL, et al. The role of regional and practice trial sites in nonrepresentative randomized cancer trial enrollment. JNCI: Journal of the National Cancer Institute. 2025;117(12):2672-2676. doi:10.1093/jnci/djaf071

BibTeX
@article{Shah2025,
  author = {Shah, Sachin J and Manz, Christopher R and Balthis, Brendan and Raman, Hari S and Abaluck, Jason and Keating, Nancy L and Agha, Leila},
  title = {The role of regional and practice trial sites in nonrepresentative randomized cancer trial enrollment},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  volume = {117},
  number = {12},
  pages = {2672--2676},
  doi = {10.1093/jnci/djaf071}
}
Kostenlos starten →